James Cheng

James Cheng supports the W4PZ USA Medical Research Acquisition Act under the Department of the Army, managing complex procurement initiatives aligned with the agency’s mission to advance warfighter health through biomedical innovation. He oversees the acquisition of advanced diagnostic, therapeutic, and analytical technologies, ensuring timely translation of laboratory research into field-deployable medical capabilities. His portfolio primarily encompasses high-technology life sciences and clinical instrumentation, requiring deep technical evaluation and compliance with federal acquisition regulations for research and development contracts. Cheng plays a critical role in bridging scientific innovation with operational readiness by facilitating contracts that meet stringent military medical standards. Cheng engages with a diverse range of vendors, including specialized manufacturers of analytical laboratory instruments, biotechnology firms, and testing laboratories delivering validated diagnostic solutions. While no single contractor dominates his award profile, he consistently collaborates with mid-sized and emerging firms capable of rapid prototyping and regulatory compliance in the biomedical space. His contracting approach emphasizes technical merit, scalability, and adaptability for austere environments, fostering partnerships with innovators who can deliver under tight developmental timelines without compromising safety or performance. Cheng’s procurement strategy reflects a strong preference for open competition, with 84.1% of awards issued without set-aside designations. However, he actively supports small business participation, with 15.9% of acquisitions structured as total small business set-asides under FAR 19.5. This demonstrates a balanced commitment to leveraging market competition while ensuring opportunities for qualified small businesses to contribute to critical military medical advancements. His primary procurement focus lies in NAICS 334516 (Analytical Laboratory Instrument Manufacturing) and 511210 (Software Publishers supporting biomedical data analytics), reflecting expertise in diagnostic instrumentation and computational life sciences. He frequently procures next-generation biosensors, point-of-care diagnostic platforms, and automated testing systems, demonstrating specialized knowledge in clinical biotechnology, molecular diagnostics, and medical device manufacturing standards.